Rehan Verjee is a co-founder and the CEO of a stealth start-up focused on enabling precision medicine through a next generation liquid biopsy platform. Previously, Rehan served as President of EMD Serono and as the Global Head of the Innovative Medicine Franchises for Merck KGaA where he led the US and global specialty medicine business through a period of significant transformation and growth that included four FDA approvals for three new medicines across cancer and auto-immune disease and a multi-billion USD deal for an EMD Serono pipeline prospect in immuno-oncology. Prior to this role, he served as Executive Vice President, Chief Marketing and Strategy officer for Merck Healthcare, Merck KGaA. Rehan is currently a member of the board of directors of Tyra Biosciences and the Massachusetts Biotechnology Council. He holds a master’s degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.